Bayer's E.L.Y. Wins “AI-based AgTech Solution of the Year” In 2025 AgTech Breakthrough Awards Program Annual Awards Program Recognizes Innovation in Agricultural & Food Technologies Around the Globe GlobeNewswire August 21, 2025 LOS ANGELES, Aug. 21, 2025 (GLOBE NEWSWIRE) — AgTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products […]

Lumo, the leader in precision irrigation technology for specialty crop growers, today announced the launch of Pump Automation, a powerful new integration with its smart valve platform. https://mma.prnewswire.com/media/2754928/Lumo_field_employee_installs_pump_automation_at_Antinori_Napa_Valley_s_Antica_Ranch.jpg “Lumo's pump automation is an absolute game changer for our team!” -Hunter Emch, Redwood Empire Vineyard Management Select growers on the North and Central Coasts are already

— Eligible Canadian patients with heterozygous familial hypercholesterolemia (HeFH) are one step closer to publicly funded access to cholesterol lowering treatment. Novartis Pharmaceuticals Canada Inc. is pleased to announce the successful conclusion of negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for the public reimbursement of Leqvio® (inclisiran) for the treatment of adults with heterozygous familial

LOS ANGELES, Aug. 21, 2025 (GLOBE NEWSWIRE) — AgTech Breakthrough, a leading market intelligence organization that recognizes the top companies, technologies and products in the global agricultural technology markets, today announced that CM Navigator, a Copenhagen Merchants company, the world's largest wheat and barley brokerage, is the recipient of “Supply Chain Analytics Solution of the

MONHEIM, Germany and Waltham, Mass. , Aug. 21, 2025 (GLOBE NEWSWIRE) — Cube Biotech, a pioneer in membrane protein stabilization and purification, and X-Chem, the global leader in DNA-Encoded Library (DEL) technology and data-driven drug discovery, are proud to announce the successful conclusion of Project DEL-MP. Project DEL-MP was a collaborative initiative demonstrating that copolymer-stabilized

SAN FRANCISCO, Aug. 21, 2025 (GLOBE NEWSWIRE) — A new survey of U.S. knowledge workers from Funmentum Labs has flipped the script on what makes a meeting great: it's not preparation, not productivity, and not even purpose. It's energy — and more than half of employees say shared laughter and spontaneous creativity are the fastest

First Nordic Metals Corp.(the”Company”or”FNM”) (TSX.V: FNM, FNSE: FNMC SDB, OTCQB: FNMCF, FRA: HEG0) is pleased to announce results to date (14 of 39 holes) from its 2025 diamond drill program at the Aida target (“Aida”), located within the Company's 100%-owned Paubäcken project (“Paubäcken” or the “Project”), in Västerbotten County, northernSweden. Key Highlights: — Multiple strong

Conference call to be held today at 10:00 AM Eastern Time ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL.F)(“Else” or the “Company”),today reported financial results for the 2025 first quarter ended March 31, 2025. The financial statements and MD&A are available on SEDARunder the Company's profile. https://mma.prnewswire.com/media/2755067/Else_Nutrition_Holdings_Inc__Else_Nutrition_Reports_2025_First_Q.jpg 2025 First Quarter Financial ResultsAll figures

Decibel Cannabis Company Inc. (the “Company” or “Decibel”) (TSXV: DB) (OTCQB: DBCCF), a market leader in premium cannabis and extract manufactured products, is pleased to announce its unaudited interim financial results for the three and six month periods ending June 30, 2025. https://mma.prnewswire.com/media/2755024/Decibel_Cannabis_Company_Inc__Decibel_Delivers_Strong_Revenue_Gr.jpg “Decibel delivered a strong second quarter with exceptional sequential growth, record international

— At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix — Z-1018 demonstrated robust immune responses in all dose arms, including a 100% humoral vaccine response rate at the dose selected for advancement,